Hepatocellular Carcinoma Clinical Trial
Official title:
Study of Hepatocellular Carcinoma in Cirrhotic Patients
The project is based on a case-control study including cirrhotic patients with (200 cases)
and without (400 controls) Hepatocellular carcinoma. The determination of sample sizes in
proteomic or spectroscopic studies has to be adapted to the high dimensional setting. The
proteomic analysis will be conducted by Clinical Innovation Proteomic Platform of Dijon. Two
approaches will be used in the proteomic study: A global approach based on the comparison of
proteomic spectra profiles obtained after mass spectrometry analysis (MALDI-TOF). The
particularity of this study with regard to previous studies is : the procedures used to
purify the sub proteomes (Five automated methods including depletion fractionation and
purification will be applied), the qualification of the generated data with the introduction
of quality controls, the high number of samples included in the study. The second approach
BIA-MS (Biomolecular interaction analysis mass spectrometry) is targeted approach allows the
capture, quantification and characterization of proteins.
The quality controls allow to quantify the various variability sources and to validate that
biological variability is higher than technical variability. All the samples will be treated
and analyzed with the same protocols, 100 samples will be used to validate the marker and
statistical models developed after analysis of the first 500 samples. The infra-red
spectroscopy analysis will be conducted by MéDIAN team, CNRS UMR 6237 of Reims university.
The first 300 samples after feature selection reference spectra, are classified into
different classes by means of mathematical classification methods such as multivariate
statistical processes of pattern recognition, neuronal networks, support vector machines and
methods of case-based classification or machine learning, genetic algorithms or methods of
evolutionary programming. The analysis of a second set of samples (300) will validate the
different mathematical classification methods developed.
In the global study the investigators will unravel the relationship between proteomic,
spectroscopic and metabolic/nutritional data. The description of these relationships will
use canonical analysis and multi-block analysis in a more general extent. The goal of these
methods is to explore relationships that may exist between several groups of quantitative
variables observed on the same set of individuals.
n/a
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
| Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
| Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
| Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
| Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
| Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
| Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
| Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
| Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |